Meeting
2020 ASCO Virtual Scientific Program
Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.
Authors
Chunmei Bai
Peking Union Medical College Hospital, Beijing, China
Chunmei Bai , Jianming Xu , Lin Shen , Jie Li , Zhiwei Zhou , Yihebali Chi , Zhiping Li , Nong Xu , Enxiao LI , Tianshu Liu , Yuxian Bai , Ying Yuan , Xingya Li , Xiuwen Wang , Jia Chen , Jieer Ying , Jing Li , Songhua Fan , Mengye Peng , Weiguo Su
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT02588170
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4613)
DOI
10.1200/JCO.2020.38.15_suppl.4613
Abstract #
4613
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
First Author: Josep M Llovet
Poster
2022 ASCO Annual Meeting
A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.
First Author: Jie Li
Poster
2022 ASCO Annual Meeting
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2021 ASCO Annual Meeting
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
First Author: Xianjun Yu